BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77.56 USD | +0.77% |
|
-5.09% | -19.56% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 273.98Cr 23TCr | Sales 2025 * | 308.9Cr 26TCr | Capitalization | 1.47TCr 1,22600Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 36Cr 3.02TCr | Net income 2025 * | 50Cr 4.2TCr | EV / Sales 2024 * | 5.12 x |
| Net cash position 2024 * | 70Cr 5.82TCr | Net cash position 2025 * | 133.7Cr 11TCr | EV / Sales 2025 * | 4.33 x |
| P/E ratio 2024 * |
42.3
x | P/E ratio 2025 * |
30
x | Employees | 3,401 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioMarin Pharmaceutical Inc.
More recommendations
More press releases
More news
| 1 day | +0.77% | ||
| 1 week | -5.09% | ||
| Current month | -3.96% | ||
| 1 month | -14.65% | ||
| 3 months | -12.63% | ||
| 6 months | -11.07% | ||
| Current year | -19.56% |
1 week
76.14
81.57
1 month
76.1493.02
Current year
76.1499.25
1 year
76.0299.56
3 years
70.73117.77
5 years
62.88131.95
10 years
55.36151.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | 01/12 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 01/02/01 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 05/20/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 04/16/04 |
| Director/Board Member | 70 | 16/05/16 | |
Randy Meier
CHM | Chairman | 65 | 14/06/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | +0.15% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 77.56 | +0.77% | 3,407,603 |
| 16/24/16 | 76.97 | -4.27% | 3,858,058 |
| 15/24/15 | 80.4 | +0.94% | 2,124,282 |
| 14/24/14 | 79.65 | -1.06% | 1,530,829 |
| 13/24/13 | 80.5 | -0.65% | 1,291,756 |
Delayed Quote Nasdaq, May 18, 2024 at 01:30 am IST
More quotes
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
21/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
77.56
USD
Average target price
109.3
USD
Spread / Average Target
+40.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.56% | 1.46TCr | |
| -2.32% | 9.26TCr | |
| +3.68% | 4.14TCr | |
| -10.90% | 3.35TCr | |
| -9.06% | 1.28TCr | |
| -11.34% | 1.16TCr | |
| -43.53% | 1.13TCr | |
| +3.75% | 896.84Cr | |
| -6.32% | 829.97Cr | |
| -9.24% | 702.39Cr |
- Stock Market
- Equities
- BMRN Stock
